NCT07015801View on ClinicalTrials.gov

CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency

NAActive, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2040

Conditions
Cytomegalovirus ViremiaCytomegalovirus PneumoniaT-Lymphocyte Immunodeficiency
Interventions
BIOLOGICAL

CMV-VST

30-40 x 10\^3 viable CD3+ cells/kg

Trial Locations (1)

Unknown

Alberta Children's Hospital, Calgary

Sponsors
All Listed Sponsors
collaborator

Alberta Precision Laboratories

UNKNOWN

collaborator

Alberta Health services

OTHER

collaborator

University of Alberta

OTHER

lead

University of Calgary

OTHER